Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.

Graham SP. et al, (2020), NPJ Vaccines, 5

ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19.

Pinto BGG. et al, (2020), J Infect Dis, 222, 556 - 563

Simultaneous Viral Whole-Genome Sequencing and Differential Expression Profiling in Respiratory Syncytial Virus Infection of Infants.

Lin G-L. et al, (2020), The Journal of infectious diseases

Biomarkers for the Discrimination of Acute Kawasaki Disease From Infections in Childhood

Zandstra J. et al, (2020), Frontiers in Pediatrics, 8

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

HODGSON S., (2020), The Lancet

Dexamethasone in hospitalized patients with Covid-19 — preliminary report

RECOVERY Collaborative Group None. et al, (2020), New England Journal of Medicine, 0, 1 - 11

Health diplomacy across borders: the case of yellow fever and COVID-19

Vanderslott S. and Marks T., (2020), Journal of Travel Medicine

Neglected Tropical Diseases

Vanderslott S., (2020), Nature and Culture, 15, 78 - 110

Development of vaccines at the time of COVID-19.

Almond J. et al, (2020), Microlife, 1

Evaluation of a standardised Vi poly-l-lysine ELISA for serology of Vi capsular polysaccharide antibodies.

Rigsby P. et al, (2020), Biologicals, 66, 21 - 29

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.

Folegatti PM. et al, (2020), Lancet Infect Dis, 20, 816 - 826

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial (vol 23, pg 861, 2020)

Folegatti PM. et al, (2020), LANCET INFECTIOUS DISEASES, 20, 148 - 148

The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world.

Sharpe HR. et al, (2020), Immunology, 160, 223 - 232

Third human challenge trial conference, Oxford, United Kingdom, February 6-7, 2020, a meeting report.

Pollard AJ. et al, (2020), Biologicals, 66, 41 - 52

E-Freeze - a randomised controlled trial evaluating the clinical and cost effectiveness of a policy of freezing embryos followed by thawed frozen embryo transfer compared with a policy of fresh embryo transfer, in women undergoing in vitro fertilisation: a statistical analysis plan.

Bell JL. et al, (2020), Trials, 21

Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.

Lambert P-H. et al, (2020), Vaccine, 38, 4783 - 4791

Advanced vaccinology education: Landscaping its growth and global footprint.

Asturias EJ. et al, (2020), Vaccine, 38, 4664 - 4670

Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel.

Ainsworth M. et al, (2020), Wellcome open research, 5, 139 - 139

Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel

Adams ER. et al, (2020), Wellcome Open Research, 5, 139 - 139

Author Correction: Phase variation in pneumococcal populations during carriage in the human nasopharynx.

Croix MDS. et al, (2020), Sci Rep, 10

Load More

«
...
32
33
34
35
36
37
38
...
»

Include forthcoming?